Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 11—November 2016
Letter

Shigella flexneri with Ciprofloxacin Resistance and Reduced Azithromycin Susceptibility, Canada, 2015

Christiane GaudreauComments to Author , Pierre A. Pilon, Gilbert Cornut, Xavier Marchand-Senecal, and Sadjia Bekal
Author affiliations: Centre Hospitalier de l’Université de Montréal–Hôpital Saint-Luc, Montreal, Quebec, Canada (C. Gaudreau, G. Cornut, X. Marchand-Senecal); Université de Montréal, Montreal (C. Gaudreau, P.A. Pilon, G. Cornut, X. Marchand-Senecal, S. Bekal); Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l’île-de-Montreal, Montreal (P.A. Pilon); Laboratoire de Santé Publique du Québec/Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, Quebec (C. Gaudreau, S. Bekal)

Main Article

Table

Antimicrobial susceptibility of the Shigella flexneri,serotype 2a pulsovar 21, isolated in Montreal, Quebec, Canada, 2015*

Antimicrobial agent Disk diffusion, mm MIC, mg/L Interpretation
Ampicillin 6 ≥32 R
TMP/SMX 6 ≥320 R
Ciprofloxacin 12 ≥4 and 8 R
Nalidixic acid 6 NA R
Ceftriaxone 33 ≤0.25 S
Cefixime 26 0.25 S
Azithromycin† 6 >256 NS
Tetracycline 6 32 R
Chloramphenicol NA >256 R
Amoxicillin-clavulanic acid 14 16 I
Ertapenem NA ≤0.5 S
Gentamicin
 21
 ≤1
 S
*I, intermediate; NA, not available; NS, nonsusceptible; R, resistant; S, susceptible; TMP/SMX, trimethoprim/sulfamethoxazole.
†Azithromycin epidemiologic cutoff values for wild-type (MIC ≤8 mg/L) and non–wild-type (MIC ≥16 mg/L) Shigella flexneri (2) and the susceptibility and resistance breakpoints for the other 11 antimicrobial agents were CLSI Enterobacteriaceae breakpoints (2).

Main Article

Page created: October 19, 2016
Page updated: October 19, 2016
Page reviewed: October 19, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external